Nursing CME Courses

Credits: 2 (AMA PRA Category 1)
Format: Online Streaming Video
Price: Free
Release Date: 9/29/2017
Expiration Date: 9/29/2018
Summary:
Credits: 1 (AMA PRA Category 1)
Format: Online Streaming Video, PDF, Online Download, Interactive Online
Price: Free
Release Date: October 19, 2017
Expiration Date: October 19, 2019
Summary:

Colorectal cancer (CRC) is the third-leading cause of cancer deaths in the U.S. While a majority of patients are diagnosed before their disease has metastasized, a fifth of patients have advanced disease at the time of diagnosis. Early detection and screening have been shown to significantly reduce CRC mortality, and screening is widely recommended for average-risk adults beginning at age 50 years, (as well as earlier for individuals at higher risk). Since the mid-1990s, the U.S. Preventive Services Task Force, American Cancer Society, and other groups have recommended several modalities for screening: fecal occult blood testing (FOBT), flexible sigmoidoscopy, colonoscopy, and barium enema. Recent years have seen the addition of newer screening technologies, including stool DNA, computed tomographic colonography, and capsule endoscopy.

By the end of the session the participant will be able to:

  • Describe present the current practice guideline recommendations with respect to colorectal cancer screening, including colonoscopy preparation, and apply them to patient cases
  • Identify the treatment modalities currently available for management of mCRC and apply them to patient cases using evidence-based medicine
  • Evaluate a treatment plan for a specific patient with mCRC to optimize safety, efficacy, and tolerability, suggesting modifications for improvement
  • Describe the challenges and barriers to care associated with treating patients with mCRC
Credits: None ()
Format: Question Bank
Price: One month $39; six months $59; one year $89.
Release Date: Continuously available
Expiration Date: Continuously available
Summary:
Credits: None ()
Format: Question Bank
Price: One month $39; six months $59; one year $89.
Release Date: Continuously available
Expiration Date: Continuously available
Summary:
Credits: 1 (AMA PRA Category 1)
Format: Online Streaming Video
Price: Free
Release Date: March 22, 2017
Expiration Date: March 21, 2019
Summary:

At the conclusion of this activity, participants will be able to:

  1. Discuss the problem of “financial harm” for individual patients
  2. List the three steps of the “First, Do No Financial Harm” framework
  3. Demonstrate strategies for discussing costs and the value of recommended medical procedures with price-sensitive patients




Credits: 1 (AMA PRA Category 1)
Format: Online Streaming Video, Multiple Formats
Price: Free
Release Date: Nov 1, 2017
Expiration Date: April 20, 2018
Summary:

Includes Topics in

  • HR deficiencies and BRCA mutations
  • Recurrent ovarian cancer
  • Data on available and emerging PARP inhibitors
  • Personalizing treatment selection
  • Companion Diagnostics
Credits: 1.0 (AMA PRA Category 1)
Format: Online Streaming Video
Price: Free
Release Date: September 04, 2017
Expiration Date: September 04, 2019
Summary:
This is an online CME self-learning program.

Rheumatoid arthritis (RA) is a systemic autoimmune disorder in which joints, typically those in the hands and feet, become inflamed, swollen, painful, and stiff. Without appropriate treatment, the inflammation may become chronic and cause irreversible destruction of bone and cartilage in the affected joints as well as contribute to the development of clinically important co-morbid conditions with attendant morbidity and mortality. The National Arthritis Data Workgroup estimates that about 1.3 million U.S. adults (0.6% of the adult population) have RA. RA imposes a considerable disease burden. Patients with RA have substantially lower health-related quality of life (QOL) than the general population with lower overall scores for physical and mental health across all age groups.The RA disease burden also is associated with increased health care resource utilization. Notably, RA patients with low QOL are twice as likely to be hospitalized as RA patients with high QOL.

Some have suggested that criteria used for the past two decades are inadequate for addressing the disease burden of RA because by the time a physician detects rheumatoid nodules or radiographic erosion, the optimal time has passed for treatment initiation, representing a gap in care relating to diagnosis of disease. Another potential gap is illustrated by studies in which researchers demonstrated that a systematic, objective approach to therapy with Disease Activity Score-driven therapy yields superior outcomes to routine care.

By the end of the session the participant will be able to:

  • Describe the pathophysiology of RA such that it might inform treatment mechanisms.
  • Describe professional guideline recommendations’ approaches to the diagnosis and treatment of RA and, where applicable, apply them to patient cases
  • Identify the currently available and emerging pharmacotherapeutic treatments for management of RA and apply them to patient cases using evidence-based medicine.
  • Evaluate a treatment plan for a specific patient with RA to optimize safety and efficacy, suggesting modifications for improvement, including the management of comorbidities.
  • Describe the challenges and barriers to care associated with treating patients with RA.